Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §3

Draft monograph: Selank — disposition

The disposition of every submission and the amendments that resulted.

Document identifier
CEI-CP-073/3
Series
Public comment period
Version
1.0
Published
22 Jun 2025
Last reviewed
22 Jun 2025
Next review
22 Jun 2026
Identifier
10.71829/cei.cp.73
Certainty
Not rated
Cycle
2025 Q2
Window
18 Apr 2025 – 16 May 2025
Status
Closed
Submissions
8

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

ReferenceRespondentPoint raisedDisposition
DRAFT-SELANK-MONOG/001Dr Rurik Haverkamp-DialloThe document set should be published in translationNot accepted
DRAFT-SELANK-MONOG/002Dr Xenia Nyquist-ObioraThe route of administration studied is not the route in which the compound is suppliedAccepted
DRAFT-SELANK-MONOG/003Dr Ludmila TollemacheThe monograph should state what the compound costsNot accepted
DRAFT-SELANK-MONOG/004Dr Frideswide NordhagenThe interaction section lists mechanisms rather than interactionsAccepted in part
DRAFT-SELANK-MONOG/005Dr Sigrún VercingetorixA near-isobaric analogue is not distinguished by the identity determination describedAccepted
DRAFT-SELANK-MONOG/006Dr Liesbeth Nordhagen industryThe monograph should reproduce the approved labelling rather than paraphrase itAccepted in part
DRAFT-SELANK-MONOG/007Dr Melisande Thorsby-NakamuraThe monograph does not tell a reader that two vials of the same compound may not contain the same thingAccepted
DRAFT-SELANK-MONOG/008Georgiana ZimmerthalThe monograph should not describe how the compound is supplied outside a regulated routeNoted, no amendment
8 submissions in total.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

DispositionCountMeaning
Accepted3The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission.
Accepted in part2Part of the submission is accepted and part is not. The secretariat response states which part is which and on what ground the remainder was declined.
Noted, no amendment1The submission raises a point the Institute accepts but that does not require a change to the draft, most often because the draft already states it elsewhere. The location is given in the response.
Not accepted2The submission is not accepted. The secretariat response gives the reason. A submission that is not accepted remains published in full; the Institute does not remove a submission because it disagrees with it.

§3.3Resulting amendments

  1. The route of administration studied is not the route in which the compound is supplied — arising from DRAFT-SELANK-MONOG/002. The assessed-outcome table now carries the studied route in every row, and a standing note appears wherever the supplied presentation differs from it.
  2. The interaction section lists mechanisms rather than interactions — arising from DRAFT-SELANK-MONOG/004. The interaction section is now divided into interactions reported in clinical use and interactions predicted from mechanism, with the second labelled as prediction. Where neither exists the section says so in one line rather than being padded.
  3. A near-isobaric analogue is not distinguished by the identity determination described — arising from DRAFT-SELANK-MONOG/005. The analytical section now states the resolving power required to discriminate the pair, names the pair explicitly, and records that an identity claim made below that resolution is not conformant with the identity standard.
  4. The monograph should reproduce the approved labelling rather than paraphrase it — arising from DRAFT-SELANK-MONOG/006. The approved indication and contraindications are now reproduced verbatim from the named authorisation with its version and date, and the posology section reports the labelled schedule and the schedules studied side by side, with the source of each stated.
  5. The monograph does not tell a reader that two vials of the same compound may not contain the same… — arising from DRAFT-SELANK-MONOG/007. A standing paragraph now appears at the head of §8 in every monograph, stating that a determination applies to the lot measured and that a label mass is not a determination.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.